Dingemanse J - Search Results

1

Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.

Ahn LY, Kim SE, Yi S, Dingemanse J, Lim KS, Jang IJ, Yu KS. Ahn LY, et al. Among authors: dingemanse j. Am J Cardiovasc Drugs. 2014 Oct;14(5):377-85. doi: 10.1007/s40256-014-0081-4. Am J Cardiovasc Drugs. 2014. PMID: 24906252 Clinical Trial.

2

Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.

Dingemanse J, Clozel M, van Giersbergen PL. Dingemanse J, et al. J Cardiovasc Pharmacol. 2002 Jun;39(6):795-802. doi: 10.1097/00005344-200206000-00004. J Cardiovasc Pharmacol. 2002. PMID: 12021573 Clinical Trial.

3

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Dingemanse J, van Giersbergen PL. Dingemanse J, et al. Clin Pharmacokinet. 2004;43(15):1089-115. doi: 10.2165/00003088-200443150-00003. Clin Pharmacokinet. 2004. PMID: 15568889 Review.

4

Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

Kummer O, Haschke M, Hammann F, Bodmer M, Bruderer S, Regnault Y, Dingemanse J, Krähenbühl S. Kummer O, et al. Among authors: dingemanse j. Eur J Pharm Sci. 2009 Nov 5;38(4):384-8. doi: 10.1016/j.ejps.2009.09.005. Epub 2009 Sep 16. Eur J Pharm Sci. 2009. PMID: 19765655

5

Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Sidharta PN, et al. Among authors: dingemanse j. Eur J Clin Pharmacol. 2011 Oct;67(10):977-84. doi: 10.1007/s00228-011-1043-2. Epub 2011 May 4. Eur J Clin Pharmacol. 2011. PMID: 21541781 Free PMC article. Clinical Trial.

6

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

Bruderer S, Aänismaa P, Homery MC, Häusler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J. Bruderer S, et al. Among authors: dingemanse j. AAPS J. 2012 Mar;14(1):68-78. doi: 10.1208/s12248-011-9316-3. Epub 2011 Dec 22. AAPS J. 2012. PMID: 22189899 Free PMC article. Clinical Trial.

7

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans.

Bruderer S, Hopfgartner G, Seiberling M, Wank J, Sidharta PN, Treiber A, Dingemanse J. Bruderer S, et al. Among authors: dingemanse j. Xenobiotica. 2012 Sep;42(9):901-10. doi: 10.3109/00498254.2012.664665. Epub 2012 Mar 30. Xenobiotica. 2012. PMID: 22458347 Clinical Trial.

8

Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjects.

Nicolas LB, Gutierrez M, Binkert C, Dingemanse J. Nicolas LB, et al. Among authors: dingemanse j. J Cardiovasc Pharmacol. 2013 Jan;61(1):42-50. doi: 10.1097/FJC.0b013e318276d444. J Cardiovasc Pharmacol. 2013. PMID: 23052033 Clinical Trial.

9

Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882.

Dingemanse J, Nicolas L. Dingemanse J, et al. Cardiovasc Ther. 2013 Oct;31(5):307-13. doi: 10.1111/1755-5922.12022. Cardiovasc Ther. 2013. PMID: 23311732 Free article. Clinical Trial.

10

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.

Atsmon J, Dingemanse J, Shaikevich D, Volokhov I, Sidharta PN. Atsmon J, et al. Among authors: dingemanse j. Clin Pharmacokinet. 2013 Aug;52(8):685-92. doi: 10.1007/s40262-013-0063-8. Clin Pharmacokinet. 2013. PMID: 23568224 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page